EC clears acquisition of joint control of Lonza Specialty Ingredients

21 June 2021
european_commission_large

The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of Lonza Specialty Ingredients of Switzerland by USA-based Bain Capital Investors and Cinven Capital Management of the UK.

Bain Capital and Cinven entered into definitive agreements to acquire Lonza Specialty Ingredients (LSI) in February this year, for a total enterprise value of 4.2 billion Swiss francs ($4.55 billion).

Lonza Specialty Ingredients, a spin-out of Swiss pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN), provides microbial control solutions and chemical technologies, as well as composite materials, performance intermediates and chemicals.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics